Mainz Biomed Partners with Thermo Fisher for Cancer Screening
Company Announcements

Mainz Biomed Partners with Thermo Fisher for Cancer Screening

Mainz Biomed B.V. (MYNZ) has released an update.

Mainz Biomed has announced a collaboration with Thermo Fisher Scientific to develop a next-generation colorectal cancer screening test. This partnership aims to leverage Thermo Fisher’s advanced technologies to enhance Mainz Biomed’s mRNA-based screening tests, which have shown significant clinical success in detecting early-stage cancer and precancerous lesions. The collaboration is set to accelerate the availability of innovative cancer screening solutions globally.

For further insights into MYNZ stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMainz Biomed, Thermo Fisher sign collaboration agreement
TheFlyMainz Biomed files to sell 30.77M ordinary shares
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App